Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.

@article{Bertrand2010CardiometabolicEO,
  title={Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.},
  author={Olivier F. Bertrand and Paul Poirier and Josep Rod{\'e}s-Cabau and St{\'e}phane Rinfret and Lawrence M. Title and Vladim{\'i}r Dz̆av{\'i}k and Madhu K Natarajan and J. Paternina-Caicedo {\'A}ngel and Nuria Batalla and Natalie Alm{\'e}ras and Olivier Costerousse and Robert de Larochelli{\`e}re and Louis Roy and Jean-pierre Despr{\'e}s},
  journal={Atherosclerosis},
  year={2010},
  volume={211 2},
  pages={565-73}
}
OBJECTIVES To assess the efficacy and safety of rosiglitazone on saphenous vein graft (SVG) atherosclerosis prevention and on modification of the global cardiometabolic risk profile. METHODS AND RESULTS This was a double-blind, randomized, placebo-controlled, multicenter trial which enrolled 193 post-CABG patients with type 2 diabetes. Atherosclerosis changes in one SVG were assessed with intravascular ultrasound at baseline and at 12 months. Serial cardiometabolic assessments were performed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…